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Clinic-Pathological Aspects of Spleen Hemophagocytic Histiocytic Sarcoma in a Dog
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ABSTRACT
Background: Histiocytes are cells that differentiate into macrophages and dendritic cell lines from bone marrow CD34+ 
stem cells. The hemophagocytic histiocytic sarcoma (HHS) is the only malignant neoplasm originating from macrophage 
lineages, being a variation of histiocytic sarcoma (HS), originated from dendritic cells. In general, the HHS shows aggres-
sive biological behavior, due to the erythrophagocytosis characteristic of this disease and overall average survival around 
seven weeks, affecting mainly Bernese Mountain Dog, Rottweiler and Golden Retriever breeds. Therefore, the objective 
of this work is to report the case of a dog with HHS, emphasizing the clinical aspects and its diagnostic method.
Case: An 8-year-old bitch Rottweiler, was attended with history of inappetence and prostration. The complete blood count 
showed normochromic normocytic anemia, monocytosis and thrombocytopenia, with serum urea levels below the reference 
value for the specie in the biochemical examination. The abdominal ultrasound highlighted splenomegaly, with heteroge-
neous parenchyma and presence of a vascularized mass and an enlarged splenic vein. Thoracic radiographic examination 
showed multifocal and rounded radiopaque structures in the pulmonary parenchyma, suggesting metastatic formation. 
Rapid serological tests for detection of the main hemoparasitosis antibodies were negative, as well as negative Coombs 
test. The animal was submitted to exploratory laparotomy with medial line access and posterior splenectomy. The spleen 
microscopic evaluation revealed neoplastic proliferation cells in mantle arrangement and solid nests areas, supported by 
a fine fibrovascular stroma. The cells had broad and eosinophilic cytoplasm, round nuclei and some pleomorphism, rude 
chromatin and evident nucleoli. It was also observed the presence of marked anisocytosis and anisocariosis, hemophago-
cytic activity, and 27 mitoses in 10 fields (40 x). There were atypical mitoses and necrosis and extensive hemorrhaged 
areas. These histopathological findings suggested a histiocytic malignant neoplasia and immunohistochemical analysis was 
performed to define a better histiocytic neoplasm origin. The neoplastic cells showed positive imunostaining for CD11d 
and Iba1 and negative imunostaining for CD3 and CD20, as well as a proliferative index of 80%, supporting the diagnosis 
of HHS in the animal’s spleen. The following hematological analyzes demonstrated persistence of anemia, worsening of 
thrombocytopenia, prolongation of activated partial thromboplastin time, hypoproteinemia with hypoalbuminemia, serum 
increase of creatinine, alkaline phosphatase and total bilirubin. Myelogram showed erythrocyte and granulocytic lineage 
hypoplasia, thrombocytic aplasia and more than 50% of macrophages in bone marrow cell population. The animal’s clini-
cal condition worsened rapidly, after successive transfusions and administration of chemotherapy with lomustine, leading 
to death 14 days after the surgery.
Discussion: HHS is the most serious clinical presentation among histiocytic disorders, conferring an extremely unfavorable 
prognosis. In addition, the scientific literature that specifically addresses the HHS is rare, with therapeutic extrapolations 
being performed for the treatment of HS from dendritic cells. The racial predisposition and clinical findings, associated 
with hematological changes, histopathological analysis and confirmation by immunohistochemistry allowed the diagnosis 
of HHS, a rare and underreported neoplasm, with aggressive biological behavior and with still inefficient treatment in 
veterinary medicine.
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INTRODUCTION
Histiocytes are cells that differentiate into 
macrophages and dendritic cell lines from bone mar-
row CD34+ stem cells, and neoplastic proliferation 
of both cells may occur [4,8,10]. The pathologies that 
affect these cells are called histiocytic disorders and 
can be classified into histiocytoses, histiocytomas, 
histiocytic sarcomas (HS) and hemophagocytic histio-
cytic sarcomas (HHS) [6,10]. Among these patholo-
gies, HHS is the only one from macrophage lineages, 
being a variation of SH, from dendritic cells [3,13]. 
In general, HHS exhibits an aggressive biological 
behavior, due to the erythrophagocytosis characteris-
tic of this disease [4,10]. Dogs can be considered an 
experimental model for hemophagocytic syndrome 
in humans, affecting mainly Bernesse Mountain Dog, 
Rottweiler and Golden Retriever [2,5,11,14]. Fur-
thermore, in HHS there is no sexual predisposition, 
being described in dogs aged 2.5 to 13 years [3]. Its 
etiology is related to mutations in tumor suppressor 
genes, initially affecting the spleen and bone marrow, 
progressing to the lungs and liver, with uncommon 
lymph nodes involvement [2,5,11,14].
The overall average survival is quite short, 
around seven weeks, leading the animal to death due 
to complications of erythrophagocytosis by neoplas-
tic cells and coagulopathies [3,6,10]. Therefore, the 
objective of this work is to report the clinical case of 
a dog with HHS, emphasizing the clinical aspects of 
the disease and its diagnostic method.
CASE
An 8-year-old bitch Rottweiler, was attended 
with history of inappetence and prostration. The com-
plete blood count showed normochromic normocytic 
anemia (hematocrit 30.6 %; reference interval [RI]: 37.3 
- 61.7 %), monocytosis (monocytes 1,740/µL; RI: 160 - 
1,120 /µL) and thrombocytopenia (platelets 82,000/µL; 
RI: 148,000 - 484,000/µL), with serum urea levels below 
the reference value for the specie in the biochemical 
examination (blood urea nitrogen 6 mg/dL; RI: 7 - 27 
mg/dL). The abdominal ultrasound highlighted spleno-
megaly, with heterogeneous parenchyma and presence 
of a vascularized mass and an enlarged splenic vein. 
Besides that, thoracic radiographic examination showed 
multifocal and rounded radiopaque structures in the 
pulmonary parenchyma, suggesting metastatic forma-
tion. Rapid serological tests1 for detection of Erlichia 
ewingii, Erlichia canis, Anaplasma phagocytophilum, 
Anaplasma platys, Borrelia burgdorferi, Dirofilaria 
immitis and Leishmania infantum antibodies were 
negative, as well as negative coombs test2. Therefore, the 
animal was submitted to exploratory laparotomy with 
medial line access and posterior splenectomy.
The macroscopic spleen examination showed 
an increase in size with bulging edges and multiple 
nodules distributed diffusely on its surface. When cut, 
multiple nodules of solid surface, heterogeneous aspect 
with brown coloration and reddish areas, with precise 
limits, were observed. The organ was fixed in 10% buff-
ered formalin, processed by routine histopathological 
technique. For microscopic evaluation, the tissue was 
Figure 1. Histiocytic sarcoma in a dog’s spleen. A & B- Neoplastic cells proliferation in mantle arrangement and solid nests areas, with round nuclei, 
pleomorphism, rude chromatin, evident nucleoli and mitosis (arrows) [H&E; 600x]. A- Hemophagocytic activity showing erythrocytes and hemosiderin 
in the cytoplasm (arrows head). B- Hemorrhaged areas (asterisks).
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stained by hematoxylin3 and eosin4 (H&E), revealing 
neoplastic cells proliferation in mantle arrangement 
and solid nests areas, supported by a fine fibrovascular 
stroma. The cells had broad and eosinophilic cytoplasm, 
round nuclei and some pleomorphism, rude chromatin 
and evident nucleoli. It was also observed the presence 
of marked anisocytosis and anisocariosis, hemophago-
cytic activity, and 27 mitosis in 10 fields (40 x). There 
were atypical mitoses and necrosis and extensive 
hemorrhaged areas (Figure 1). The histopathological 
findings suggested a histiocytic malignant neoplasia 
and immunohistochemical analysis was performed to 
define a better histiocytic neoplasm origin.
The immunohistochemistry evaluated the 
CD11d5, Iba16, CD37, CD208 and Ki-677 immuno-
expression. The neoplastic cells showed positive 
immunostaining for CD11d and Iba1 and negative 
immunostaining for CD3 and CD20, as well as a pro-
liferative index of 80 %, supporting the diagnosis of 
HHS in the animal’s spleen (Figure 2).
After the surgical procedure, it was observed 
the persistence of normochromic normocytic anemia, 
worsening of thrombocytopenia (platelets 2,000/µL), 
prolongation of activated partial thromboplastin time 
(aPTT) (183 s; RI: 72 - 102 s), hypoproteinemia (total 
protein 3.7 g/dL; RI: 5.2 - 8.2 g/dL) with hypoalbu-
minemia (albumin 1.6 g/dL; RI: 2.3 - 4.0 g/dL), serum 
increase of creatinine (1.9 mg/dL; RI: 0.5 - 1.8 mg/dL), 
alkaline phosphatase (278 U/L; RI: 23 - 212 U/L) 
and total bilirubin (2.8 mg/dL; RI: < 0.9 mg/dL), in 
addition to mild nephropathy and hepatomegaly in ab-
dominal ultrasound. Myelogram showed erythrocyte 
and granulocytic lineage hypoplasia, thrombocytic 
aplasia and more than 50 % of macrophages in bone 
marrow cell population. The animal’s clinical condi-
tion worsened rapidly, after successive transfusions 
and administration of chemotherapy with lomustine9 
(Citostal - 90 mg/m2), leading to death 14 days after 
surgery.
Figure 2. Immunohistochemistry for hemophagocytic histiocytic sarcoma diagnostic in a dog’s spleen. A- Positive immunostaining for CD11d. B- Posi-
tive immunostaining for Iba1. C- Negative immunostaining in neoplastic cells for CD3. D- Proliferative index of 80% (Ki67).
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DISCUSSION
HHS is the most serious clinical presentation 
among histiocytic disorders, conferring an extremely 
unfavorable prognosis [10]. Due to aggressive biologi-
cal behavior and nonspecific clinical manifestation, 
early diagnosis is very rare to be performed, resulting 
in a low survival time for patient [8]. In addition, the 
scientific literature that specifically addresses the HHS 
is rare, with therapeutic extrapolations being performed 
for the treatment of HS from dendritic cells [10]. Such 
statements could be seen in the present report with a 
14-day survival.
The hematological alterations, initially unspe-
cific, were elucidated after the definitive diagnosis of 
HHS, obtained through the immunophenotyping of 
the affected organ. The anemia observed in the patient 
can be explained due to the activity of mutated mac-
rophages that performed erythrophagocytosis. This 
anomalous cellular behavior is consistent with the 
literature that describes not only red blood cells, but 
also hemosiderin in the cytoplasm of macrophages, 
although leukocyte and platelet phagocytosis is not so 
common [11,15]. Monocytosis, also observed in this 
case, can also be explained because monocytes are cells 
that differentiate into macrophages after migration to 
tissues [16,17]. In addition, spleen and bone marrow 
are organs in which this type of phagocytic activity of 
neoplastic cells is usually observed, manifesting clini-
cally through diffuse splenomegaly with ill-defined 
masses [3,4,10]. The myelogram, in its turn, showed 
the presence of macrophages representing more than 
50% of the cell population, thus being an important 
feature in the differentiation of hemophagocytic syn-
dromes [18].
Biochemical and hemostatic alterations in 
the serum evaluation are also cited in the literature, 
highlighting hypoalbuminemia, hypercholesterol-
emia, hypoproteinemia, increased aPTT and discrete 
hyperbilirubinemia due to the neoplastic inflamma-
tory process, all observed in the report with exception 
hypercholesterolemia, without interference in the final 
diagnosis [6,10]. Increased creatinine and decreased 
urea, as well as increased serum alkaline phosphatase 
are associated with disease progression in this case 
[1,7]. The observed thrombocytopenia is in line with 
the literature, which points a decrease in the absolute 
number of platelets due to their consumption, exac-
erbating the coagulation disorder [10]. It is essential 
that in the diagnosis of HHS, other anemia possibilities 
are discarded, such as hemoparasitosis and immune-
mediated hemolytic diseases [8,10]. Therefore, infec-
tions by Erlichia ewingii, Erlichia canis, Anaplasma 
phagocytophilum, Anaplasma platys, Borrelia burg-
dorferi, Dirofilaria immitis and Leishmania infantum 
were discarded through immunochromatography, as 
well as immune-mediated hemolytic anemia by the 
negative coombs test.
In the histopathological analysis of the spleen, 
high atypia and intense hemophagocytic activity of 
neoplastic cells were observed, justifying the initial 
hematological findings [10,11,15]. Although the his-
topathological findings suggest the diagnosis of HS of 
macrophage origin, the confirmatory diagnostic can 
only be performed through the immunophenotypic 
characterization by the immunohistochemistry tech-
nique [4,8,15].
The HHS macrophages in the spleen and bone 
marrow express an antigenic profile on the membrane 
that allow differentiates them from dendritic cells in 
the HS [8-10]. These macrophages express CD11d, a 
beta-2 integrin responsible for the molecules adhesion, 
whereas dendritic cells express predominantly CD11c 
[10]. In addition, the identification of histiocytic pro-
liferation in general can be evidenced by the expres-
sion of the ionizing calcium-binding protein 1 (Iba1) 
[9]. Thus, the positive immunostaining for Iba1 and 
CD11d in the neoplastic cells in this report supported 
the diagnosis of HHS.
On the other hand, hepatosplenic T-cell lym-
phoma is also characterized by anemia and thrombo-
cytopenia, like hemophagocytic syndrome, and can be 
a differential in the diagnosis of HHS, having positive 
immunostaining for CD3 [9]. The fact that lympho-
mas in general also express β-2 integrins makes it 
important to differentiate a possible lymphoid origin 
of these tumors, observing the immunoexpression of 
CD3, CD79a and CD20, for example in these cases 
[8]. Considering these informations, the negative im-
munostaining of the neoplastic cells in this study for 
CD3 and CD20 could confirm the final diagnosis of 
HHS in the spleen.
The treatment performed on this patient, how-
ever, was merely palliative, since the rapid evolution 
did not allow the realization of more complex chemo-
therapy protocol. The splenectomy associated with 
adjuvant chemotherapy with lomustine and succes-
sive blood transfusions were not sufficient to contain 
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neoplastic progression. Lomustine is a highly lipophilic 
nitrosurea class of antineoplastic, featuring high pen-
etrability of this drug in tissues, being the first choice 
for the treatment of histiocytic sarcomas [12]. Due to 
the advanced stage of the disease, with radiological 
signs suggestive of pulmonary metastasis, the patient 
died before it was possible to perform the second dose 
of chemotherapy with the maximum tolerated dose.
The racial predisposition and clinical findings, 
associated with hematological changes, histopatho-
logical analysis and confirmation by immunohisto-
chemistry allowed the diagnosis of HHS, a rare and 
underreported neoplasm, with aggressive biological 
behavior and with still inefficient treatment in veteri-
nary medicine.
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